Takeda Pharmaceutical spinout HilleVax broke the biotech IPO drought with a $200 million stock market debut for clinical development of a norovirus vaccine. Two eye health companies marked the other IPO activity: Belite Bio went public while Bausch + Lomb set financial terms for what could become one of the biggest IPOs of the year.
Join Presidio, Cisco Meraki and Purple AI on Thursday, May 5th from 3PM - 4PM EST to learn how you can transform any location into a highly-intelligent smart space.
Staffing shortages can slow down trial timelines and negatively affect patients, who have less time with the physicians and nurses providing their care. But a few flexible, integrated systems that work for both clinical research sites and sponsors could help alleviate these issues and speed up research.
By Brett Kelman, Kaiser Health News Sunday, May 1, 2022 1:55 PM
There have been several incidents of hospital staffers searching computerized medication cabinets with three or fewer letters and then administering or nearly administering the wrong drug. Hospitals are not required to report most drug mix-ups.
Cost is a primary reason people avoid or delay care, even when they are insured. But increasingly consumers are talking with providers, shopping around and taking advantage of cost transparency tools to access the care they need.
To truly move the needle on healthcare costs and outcomes, we need a more integrated care delivery model. This should fill in the gaps between scheduled appointments and foster more regular connections between healthcare consumers and their providers.
In our conversation, Adrienne McFadden, who at one time was a practicing physician, speaks about the evolution of the company to more of a curated matchmaker connecting and guiding people to the best care available. Listen Now!
MedCity News 611 Broadway New York, NY 10012 United States
You received this email because you are subscribed to MedCity Daily Digest from MedCity News.
Update your email preferences to choose the types of emails you receive.
No comments